Skip to main content

Table 1 Clinical characteristics of the patients at baseline

From: Everolimus-eluting bioresorbable scaffolds and metallic stents in diabetic patients: a patient-level pooled analysis of the prospective ABSORB DM Benelux Study, TWENTE and DUTCH PEERS

Baseline clinical characteristic

EE-BRS (n = 150)

EES (n = 249)

p-value

Age (years)–mean ± SD

64.3 ± 10.1

67.1 ± 10.2

<0.01

Sex (male)–no.(%)

108 (72.0)

159 (63.9)

0.09

Body-mass index (kg/m2)–mean ± SD; no.

29.5 ± 5.1, 148a

29.3 ± 4.8, 221a

0.63

Risk factors–no.(%)

 Insulin-treated diabetes mellitus

52 (34.7)

163 (34.5)

0.98

 Arterial hypertension

104 (69.3)

176 (70.7)

0.78

 Hypercholesterolemia

100 (66.7)

157 (63.1)

0.47

 Family history of cardiovascular disease

59 (39.3)

131 (52.6)

0.01

 Current smoker

35 (23.3)

50 (20.1)

0.44

Medical history–no.(%)

 Previous acute coronary syndrome

28 (18.7)

59 (23.7)

0.24

 Previous PCI

37 (24.7)

54 (21.7)

0.49

 Previous CABG

8 (5.3)

24 (9.6)

0.13

 Chronic renal failureb

6 (4.0)

12 (4.8)

0.70

Clinical presentation–no.(%)

 Acute coronary syndrome

73 (48.7)

120 (48.2)

0.93

  Myocardial infarction

47 (31.3)

74 (29.7)

0.73

  Unstable angina pectoris

26 (17.3)

46 (18.5)

0.77

 Non-acute coronary syndrome

77 (51.3)

129 (51.8)

0.93

  1. Shown are the clinical characteristics at baseline for both patient groups
  2. EE-BRS everolimus-eluting bioresorbable scaffolds, EES everolimus-eluting stents, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting
  3. aPlus–minus values are mean ± standard deviation (SD) and the number in italica represent the known total of which the variable was calculated
  4. bRenal insufficiency was defined as serum creatinine level of ≥ 130 µmol per liter. A p-value < 0.05 was considered as statistically significant